To approximate the effect of prolonged storage on safety and immunogenicity, healthy children were given a single dose of the currently marketed live attenuated varicella vaccine (3625 pfu) or of a partially heat-inactivated vaccine (1125 or 439 pfu), The 3 doses had similar antigen content (attenuated plus inactive virus particles). The vaccine was well tolerated. No significant differences in adverse reactions were observed. Although the seroconversion rates were excellent at each dose (?:98%), the higher doses resulted in significantlygreater geometric mean antibody titers at 6 weeks (10.5 and 10.6 ELISA U/mL) compared with the 439 pfu dose (5.7 ELISA U/mL), P ::0:; .01. One year after immunization, differences in antibodies were similar to the 6-week postimmunization results. Results indicate that until the date of expiry, the vaccine's immunogenicity will be preserved and there will be no clinically important changes in type or frequency of adverse events. In most previous studies, vaccine was prepared by filling a single-dose vial with a specified number of plaque-forming units (Pfu) or by diluting a known quantity of pfu to obtain the desired immunizing dose [3] [4] [5]. Although these methods vary the total immunizing dose, the ratio of attenuated to inactive viral antigen particles remains similar. These methods may not accurately reflect the conditions that occur with prolonged storage, when the antigen dose remains the same while the ratio of attenuated to inactive virus particles decreases. This study evaluated the immunogenicity and safety of the currently marketed live attenuated varicella vaccine after partial heat inactivation to approximate the effect of prolonged storage.
Dose Titration Study of Live Attenuated Varicella Vaccine in Healthy Children
To approximate the effect of prolonged storage on safety and immunogenicity, healthy children were given a single dose of the currently marketed live attenuated varicella vaccine (3625 pfu) or of a partially heat-inactivated vaccine (1125 or 439 pfu), The 3 doses had similar antigen content (attenuated plus inactive virus particles). The vaccine was well tolerated. No significant differences in adverse reactions were observed. Although the seroconversion rates were excellent at each dose (?:98%), the higher doses resulted in significantlygreater geometric mean antibody titers at 6 weeks (10.5 and 10.6 ELISA U/mL) compared with the 439 pfu dose (5.7 ELISA U/mL), P ::0:; .01. One year after immunization, differences in antibodies were similar to the 6-week postimmunization results. Results indicate that until the date of expiry, the vaccine's immunogenicity will be preserved and there will be no clinically important changes in type or frequency of adverse events.
The safety, immunogenicity, and efficacy of live attenuated varicella vaccine, licensed in the United States for use in persons~12 months old, has been demonstrated in> 10,000 study participants. Routine administration of varicella vaccine to healthy susceptible children has been recommended by the In most previous studies, vaccine was prepared by filling a single-dose vial with a specified number of plaque-forming units (Pfu) or by diluting a known quantity of pfu to obtain the desired immunizing dose [3] [4] [5] . Although these methods vary the total immunizing dose, the ratio of attenuated to inactive viral antigen particles remains similar. These methods may not accurately reflect the conditions that occur with prolonged storage, when the antigen dose remains the same while the ratio of attenuated to inactive virus particles decreases. This study evaluated the immunogenicity and safety of the currently marketed live attenuated varicella vaccine after partial heat inactivation to approximate the effect of prolonged storage.
Methods
Subjects. Healthy 1-to 6-year-old children were enrolled in the study from a private, mostly middle class, white, population. Subjects had no history of varicella, zoster, or exposure to these diseases for ?:4 weeks before immunization. Subjects were excluded if they were immunocompromised or had received immune globulin or blood products within 3 months before immunization.
Vaccine. Live attenuated varicella vaccine (VARIVAX) was derived from the Oka strain and developed by Merck Research Laboratories as previously described [4, 5] . The vaccine used in this trial (lot C-W591), produced using the same process as the licensed vaccine, was one of five consistency lots manufactured in 1991 [5] . To approximate the conditions of long-term storage and reconstitution, 2 of 3 groups of single-dose vials containing 3625 pfu of lyophilized vaccine were exposed to a temperature of 32°C for 2 and 12 days, yielding vaccine that contained 1125 and 439 pfu/O.5 mL, respectively. Infectivity of the vaccine was measured by plaque assay with a relative SD of 15%. The antigen content of each preparation was similar before (0.9 U/O.5 mL) and after heat inactivation (0.9-1.0 U/O.5 mL). Vaccine was stored at -20°C until reconstituted with sterile distilled water immediately before administration.
Study design. After a medical history was obtained, children were randomized to receive one 0.5-mL subcutaneous dose of varicella vaccine containing 439, 1125, or 3625 pfu. Children were not immunized within 1 month of another immunization or during a febrile illness.
Signs and symptoms, including daily temperatures, were recorded by parents on a standardized reporting form for 42 days after immunization. Parents were asked to notify the study physicians if their child developed a varicella-like rash at the injection site or elsewhere, developed temperature ?:38.9°C, or had any unusual reaction. Although the study was designed as "open," parents and study physicians were unaware of the dose of vaccine given. Blood was obtained by venipuncture before immunization, 6 weeks later, and yearly thereafter. Routine serologic data are available for 2 years.
Parents were requested to notify study physicians if they thought their child developed chickenpox any time after immunization; these children were seen by a study physician. If chickenpox was even a remote possibility, a request for acute and convalescent blood was made. If a child was suspected of having chickenpox after immunization, yearly blood specimens were not obtained. Breakthrough and exposure information was also collected when participants returned for antibody persistence serum sampling.
Serologic assay. Serum was frozen until assayed at Merck Research Laboratories. Humoral antibody to varicella-zoster virus (VZV) was measured by a glycoprotein-based ELISA as previously described [6] and reported in ELISA units (EU). Pre-and 6-week postimmunization sera from each subject were assayed simultaneously. One-and 2-year samples were tested separately in the same laboratory using standardized assays. Suspected breakthrough chickenpox was considered confirmed if there was an increase in antibody titer between acute and convalescent specimens of ?:4-fold, a convalescent antibody titer achieved a predetermined antibody value that correlated with breakthrough chickenpox, or both [7] .. Laboratory personnel were unaware of the subjects' vaccine assignments. Cellular immunity was not assessed.
Statistical analysis. All tests of significance were two-sided, and results were considered significant at P~05. No adjustment was made for multiple pairwise comparisons. Geometric mean (GM) antibody values were compared by analysis of variance, as the log-transformed values appeared normally distributed. Proportions of subjects with 6-week antibody titers ?:5.0 EU/mL were compared by Fisher's exact test. Proportions of subjects with adverse events among groups were compared using X 2 or Fisher's exact test as appropriate. Due to the small sample size, nonsignificant P values do not necessarily imply similar immune responses.
Results
Demographics. Fifty children were enrolled at each dose level; all completed the study to 6 weeks. At enrollment, the mean age (2.9-3.2 years), gender, and percentage of children initially seropositive (2%-8%) were similar for the 3 groups. A total of 135 children completed the study for 1 year and 107 for 2 years; 88 and 85 subjects were actively surveyed for breakthrough chickenpox in years 3 and 4, respectively.
Safety (table 1). The vaccine was generally well tolerated. No serious adverse experiences occurred. No statistical differences in local or systemic adverse events, including oral temperatures~38.9°C (10%-16%), were observed, and none were considered clinically important.
Immunogenicity (table 2) . Six weeks after immunization, 98%-100% of subjects in each group seroconverted. The GM antibody responses of children who received 1125 or 3625 pfu were significantly greater than in children who received 439 pfu (P~.01). The percentage of children achieving antibody titers~5.0 EU/mL was greater in the group given 3625 pfu (P~.01) than in the group given 439 pfu. Although sera for all children assayed 1 year after immunization remained positive, the children who received the 2 higher doses had higher GM antibodies than the children who received 439 pfu. All sera assayed 2 years after immunization remained positive; GM antibody values were 11.0, 21.6, and 12.1 EU/mL in the groups receiving 439, 1125, and 3625 pfu, respectively. These differences were not statistically different or clinically important. Breakthrough varicella surveillance. During 4.3 years of surveillance, parents of 15 children reported 16 episodes of suspected breakthrough varicella. As the study physicians were also the participants' primary care physicians, we believe most breakthrough cases were captured. Six children with suspected breakthrough varicella had received 439 pfu (6-week postimmunization titers: 1.6, 2.3, 5.1, 5.7, 6.8, and 13.0 EU/mL), 6 others received 1125 pfu (6-week postimmunization titers: 4.0, 4.4, 5.0, 11.9, 15.1, and 16.1 EU/mL), and 3 received 3625 pfu (6-week postimmunization titers: 1.5, 2.7, and 16.1 EUI mL). Breakthrough cases occurred 14-40 months after immunization. All but 4 illnesses were seen by a study physician. Each child with suspected chickenpox had mild disease (median number of maximum lesions and median number of maximum vesicles, 25 and 0, respectively), consistent with previous reports [7] [8] [9] . Acute and convalescent serum specimens, available for 9 episodes of suspected chickenpox, confirmed the disease in 7 children.
Another 3 children had only convalescent serum tested, but comparison with previous surveillance titers was possible. In the first child, 5 months after an antibody level of 1.5 EU/mL at year 1, suspected chickenpox occurred. Six weeks later, his antibody level was 39.5 EU/mL at year 2. In a second child, 7 weeks after a serum antibody level of 2.3 EU/mL at year 2, suspected chickenpox occurred. The child's antibody titer was 67.5 EU/mL 2 months later. Although the >4-fold antibody increase in these children suggests recent infection with VZV, the lack of an acute serum specimen and the fact that both convalescent values were lower than those usually associated with recent breakthrough chickenpox in our patients (200-11,563 EU/mL) and in other studies (558-5000 EU/mL) [7] prevents definitive diagnosis. The third child developed suspected chickenpox 10 months after he had an antibody titer of 3.6 EU/mL; 3 weeks later, the level was 4213 EU/mL.
Discussion
In this study, heat inactivation rather than dilution was used to generate decreased live attenuated virus titers while maintaining a constant antigen level. This method reflects more accurately the amount of total antigen (attenuated virus plus inactive virus particles) of the vaccine at expiry, when stored and administered as directed. There were no statistically significant differences in the type or frequency of adverse events with various live virus quantities over an 8-fold range or with various ratios of attenuated to inactive virus. The frequency of temperatures~38.9°C was similar to that in a published double-blind placebo-controlled study in which ,...., 15% of children who received the placebo had oral temperatures of~38.9°C during 58 days of follow-up [10] .
Although a dose of 439 pfu resulted in excellent 6-week seroconversions (98%) compared with doses of 1125 and 3625 pfu (each 100%), the 6-week OM antibody value was significantly lower in this group than in children who received higher vaccine doses. The percentage of children achieving 6-week antibody levels~5.0 EU, a value roughly correlated with the probability of developing chickenpox after immunization [8] , was also significantly lower in the group receiving 439 pfu than in the group given 3625 pfu. Higher OM antibody values were observed 1 year after immunization for the groups given 1125 and 3625 pfu of vaccine than in children given 439 pfu. In year 2, subjects who received 1125 pfu had higher OM antibody titers than the groups given 439 or 3625 pfu. These differences, which probably reflect differences in number of exposures, timing of exposure to natural disease, and blood sampling, were not statistically different.
Breakthrough chickenpox occurred occasionally in recipients of all 3 doses. As this study was designed to assess only safety and humoral immunogenicity, it was not possible to detect statistically significant differences in protection among the 3 groups.
Our results were similar to those of a study of a prelicensure varicella vaccine that was partially inactivated by exposure to ambient temperature [11] . In that study, initially seronegative children developed significantly lower humoral antibody levels after receiving vaccine with similar antigen content but lower attenuated virus content. Cell-mediated immunity (CMI) was similar in the 3 groups 1 year after immunization. Although the exact CMI mechanism involved in response to immunization, infection, reinfection, reactivation of latent VZV, and booster doses has not been defined, it is apparent that both humoral and CMI responses play major roles in protecting against VZV.
In another study of seronegative children, 2 vaccine preparations that varied in antigen content but maintained similar pfu were administered [12] . Six weeks after immunization, the humoral antibody response was similar, but the group receiving vaccine with the higher antigen content had a greater CMI response. The authors suggested that inactive virus particles might prime for a response to replicating attenuated virus. In contrast, in seropositive adults, the humoral and CMI responses seem to be similar after attenuated vaccine (attenuated virus plus inactive virus particles) or completely inactivated vaccine containing a similar antigen content [13, 14] . From the results of our study and of those cited, it seems that in seronegative persons the immune response can be modulated by varying the content of either attenuated virus or antigen, whereas in seropositive subjects the immune response seems to be based on antigenic content.
Results of this study provide reassurance that as long as the vaccine is stored properly and administered within 30 min of reconstitution, the minimum approved vaccine potency at the expiration date (1350 pfu) will ensure that the vaccine's immunogenicity will be preserved and there will be no clinically important changes in type or frequency of adverse events. While our study documents that doses of 439 pfu are immunogenic, doses containing 1125 or 3625 pfu resulted in higher GM antibody values. Our results suggest that to ensure adequate immunogenicity the vaccine should contain~1125 pfu of live attenuated varicella virus at the time of administration.
